Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Tecentriq-Avastin Combo Approved in Europe for Advanced or...
2 Systemic Therapy Advances Provide More Treatment Options in HCC
3 Avastin and Tecentriq combination wins approval in China and Europe
4 Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC
5 Immunotherapy Combinations Emerge as Likely Standard for Future HCC Management
6 Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm
7 'Momentous' Data for First-Line Combo in Liver Cancer
8 The European Commission has approved Roche's Tecentriq in conjunction with Avastin
9 Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial
10 Roche gets EC approval for Tecentriq-Avastin combo to treat liver cancer
11 Drug Duo Is Promising in Older Patients With Advanced HCC
12 Dr. Harding on the Goal of the IMbrave150 trial in HCC
13 Long HCC pipeline marks change for previously stagnant market, says an
14 FDA Approves Atezolizumab Combo for Unresectable or Metastatic Hepatocellular Carcinoma
15 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
16 FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
17 Unlocking the Potential of Targeted Treatment Options for HCC
18 Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma
19 Post Conference Perspectives: Immunotherapy Combinations for Unresectable HCC
20 Roche's Tecentriq/Avastin combination approved by European Commission
21 Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC
22 FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
23 Multidisciplinary Care to Provide Best Possible Outcomes in HCC
24 FDA OKs Atezolizumab Plus Bevacizumab for Frontline Treatment of Advanced Liver Cancer
25 PROs Provide Insight On Atezolizumab/Bevacizumab Benefit in HCC
26 New Advancements Change HCC Treatment
27 Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC
28 Europe approves Roche's Tecentriq liver cancer combination
29 Tecentriq-Avastin Combo for Liver Cancer Recommended for EU Approval
30 FDA Approves Genentech's Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
31 Frontline Atezolizumab Plus Bevacizumab Prolongs Survival in HCC
32 Tecentriq Plus Avastin Now Approved for Liver Cancer
33 Atezolizumab + bevacizumab approved by FDA for unresectable HCC
34 Roche files for US approval for Tecentriq plus Avastin combo
35 In Light of Recently Approved Regimens, Sequencing Strategies Are Under Discussion in HCC
36 Roche's Tecentriq in combination with Avastin approved in China for people with liver cancer
37 FDA approves Roche's Tecentriq in combination with Avastin for people with the most common form of liver cancer
38 First-Line Combo Improves Survival in Advanced HCC
39 Enhancing Survival of HCC Patients in The New Era
40 Atezolizumab + Bevacizumab Helps Patients Maintain Quality of Life in Colorectal and Liver Cancers
41 A 61-Year-Old Man With Stage 4 Hepatocellular Carcinoma
42 Genentech's Tecentriq-Avastin Combo Approved for HCC, an Improvement on Standard of Care
43 Roche's Tecentriq/Avastin combo wins US approval
44 El-Khoueiry Elucidates Recent Updates in the Rapidly Evolving HCC Treatment Paradigm
45 Frontline Atezolizumab and Bevacizumab Meet PFS, OS Endpoints in Phase III HCC Trial
46 Singal and Kim Talk Trials and Treatments for HCC
47 Atezolizumab Combo Improves Survival in Unresectable HCC
48 Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
49 Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC
50 Atezolizumab in Combination with Bevacizumab May Be Effective for Patients with HCC
51 Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC
52 QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC
53 New Drug Combo Potentially Practice Changing in Advanced HCC
54 Roche's Tecentriq, Avastin combo improves OS in unresectable HCC
55 FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for...
56 'Tecentriq opens immune-based combo therapy era for liver cancer'
57 Combination of Atezolizumab + Bevacizumab Improves Survival in Hepatocellular Carcinoma
58 ILCA Data Reignite Interest in AFP as a Biomarker for HCC
59 Updates in Frontline Treatment of Metastatic Liver Cancer
60 Abou-Alfa Hails "Positive and Disruptive" Impact of Novel Combinations in HCC
61 New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC
62 Dr. Somer on the Clinical Implications of Atezolizumab/Bevacizumab Approval in HCC
63 Atezolizumab/Bevacizumab Approval Leaves Second-Line Questions in HCC
64 Atezolizumab plus bevacizumab extends survival in unresectable HCC
65 Exploratory Study Finds Genomic Markers of Response to Tecentriq, Avastin in Advanced Liver Cancer
66 Roche Tecentriq, Avastin combo gets positive CHMP opinion for liver cancer
67 First-Line Systemic Strategies Continue to Evolve in HCC
68 Health Canada grants market authorization for Tecentriq® in combination with bevacizumab,[1] the first immunotherapy combination treatment, for the most common form of liver cancer[2]
69 A 69-Year-Old Man With Stage 4 Hepatocellular Carcinoma
70 Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC
71 Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC
72 Roche's Ph III cancer immunotherapy trial reveals positive results for liver cancer
73 Liver Cancer Patients Live Longer with Tecentriq-Avastin, Data Show
74 Locoregional Treatments Still Key in HCC Care
75 Atezolizumab-bevacizumab combination extends survival in unresectable HCC
76 Combination of Atezolizumab and Bevacizumab Shows Early Efficacy in Unresectable HCC
77 The debate continues: How to treat early-stage HCC
78 Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light
79 Onc Daily: Liver Cancer Breakthrough, Medicaid Expansion
80 Roche files Tecentriq, Avastin combo as a liver cancer therapy
81 Dr. Salem on Locoregional Therapy Versus Systemic Therapy in HCC
82 FDA Holds Off on Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC
83 Why is Tecentriq+Avastin potent primary therapy for liver cancer?
84 Hope Persists as Treatment Landscape for HCC Expands Dramatically
85 New data on emerging treatments for liver cancer raise hope for advanced disease patients
86 BRIEF-Roche Gives Update On Tecentriq For Treatment Of Liver Cancer
87 US FDA approved Roche's Tecentriq in combination with Avastin
88 FDA approves immunotherapy regimen for advanced liver cancer
89 Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm
90 Biomarkers, Patient Factors Inform HCC Treatment Decisions Beyond Frontline Setting
91 Studies Investigate Multiple Types of Therapies in HCC
92 Optimized Sequencing Remains a Top Priority in HCC
93 Tecentriq, Avastin combination improves survival in unresectable HCC
94 Team-Based Approach Essential in HCC Care
95 Roche takes aim at Bayer's liver cancer share with big Tecentriq-Avastin win
96 First-Line IO Yields Long Survival in MSI-H/dMMR Colon Cancer
97 Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
98 China National Medical Products Administration grants approval of Roche's Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
99 Tecentriq-Avastin combo hits endpoint in liver cancer
100 Investigators Test Immunotherapy Combo in HCC